AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 72 min read$AGYS

SRINIVASAN RAMESH sold $21.3M of AGYS

SRINIVASAN RAMESH (President & CEO) sold 197,410 shares of AGILYSYS INC (AGYS) at an average of $107.82 ($106.60–$109.63, $21.29M total) across 4 trades over 2026-08-05 to 2026-08-07.

Original reporting
SEC EDGAR · SRINIVASAN RAMESH
Published Aug 7, 2026, 9:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AGYS
Neutral
medium confidence
Mentioned
$AGYS
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGYSNeutralLow
01

Why it matters

The market may reprice short-term sentiment around insider confidence, but there is no accompanying guidance, deal, or operational update in the text.

02

Market read

A large CEO sale is disclosed, which can affect near-term sentiment and options positioning, but it does not provide new fundamentals.

03

What to watch

The absence of a stated 10b5-1 plan can increase perceived risk, but without additional context (e.g., compensation structure, tax events) it is hard to infer intent.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-07, covering sales executed 2026-08-05 to 2026-08-07

Background

This is an SEC Form 4 insider transaction by AGILYSYS President and CEO Srinivasan Ramesh.

Company-level read

Ticker impact

$AGYSNeutralMedium confidence
Context

AGILYSYS CEO sold about $21.29M of AGYS shares in four open-market trades from 2026-08-05 to 2026-08-07.

Expected impact

Likely modest negative bias for the next few sessions, with limited follow-through unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary Form 4 disclosure with sizable value, but it does not include new company fundamentals or a 10b5-1 plan, so the market may treat it as mixed signal rather than a catalyst.

Market effects

Sector

Limited sector read-through; this is company-specific insider activity rather than an industry shock.

Regional

No clear regional spillover indicated by the filing alone.

Global

Minimal global relevance; the disclosure is localized to AGILYSYS insider trading.

Counterpoint

What could challenge this read

The CEO may be selling for diversification, taxes, or pre-planned liquidity needs, so the signal could be largely non-informational.

Key entities

  • issuer
    AGILYSYS INC

    US-listed company whose CEO executed open-market sales totaling about $21.29M.

  • insider
    SRINIVASAN RAMESH

    President and CEO who sold 197,410 shares across four trades at $106.60 to $109.63.

Read at source← All news

Related articles

JUL 28
$AGYSHighAI 8/10

Why Agilysys (AGYS) Stock Is Up Today

Agilysys (NASDAQ: AGYS) shares rose 11.6% after the company reported Q2 results above expectations and raised full-year revenue guidance. Revenue was $87.68M vs $86.2M expected, with adjusted EPS $0.49 vs $0.40. Full-year revenue guidance midpoint was lifted to $370.5M.

financialcontent.com4 min
JUL 28
$AGYSMed

Agilysys Inc (AGYS) Q1 2027 Earnings Call Highlights: Record Revenue and Raised Guidance

Agilysys (AGYS) reported Q1 2027 earnings call highlights, citing record revenue and raised guidance. The CFO said the increase was driven by stronger-than-expected subscription sales and backlog conversion, while product and professional services remain within prior guidance. CEO comments covered RFP win rates, Marriott PMS rollout lessons, price-sensitive markets, and AI’s role in hospitality software.

yahoo.com4 min
JUL 27
$AGYSMedAI 8/10

Agilysys: Fiscal Q1 Earnings Snapshot

Agilysys Inc. (AGYS) reported fiscal Q1 profit of 32 cents per share, or 49 cents adjusted, versus Zacks’ four-analyst estimate of 40 cents. Revenue was $87.7 million versus $85.9 million expected. Full-year revenue guidance is $368 million to $373 million. Shares were down 13% YTD, ending Monday at $103.24.

local3news.com2 min
JUL 27
$AGYSMed

Agilysys (NASDAQ:AGYS) Surprises With Q2 CY2026 Sales

Agilysys (NASDAQ:AGYS) reported Q2 CY2026 revenue of $87.68 million, up 14.3% year on year and 1.7% above Wall Street estimates. Full-year revenue guidance midpoint is $370.5 million, 0.7% above consensus. Non-GAAP EPS was $0.49, 21.7% above consensus, with subscription growth of 26% and professional services revenue of $19.6 million.

financialcontent.com4 min
JUL 27
$AGYSHigh

AGILYSYS INC (AGYS): Results of Operations and Financial Condition

AGILYSYS INC (AGYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agys-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AGILYSYS ANNOUNCES RECORD REVENUE OF $87.7M IN FISCAL 2027 FIRST QUARTER Quarter Adjusted EBITDA of 20.8% and Adjusted EPS of $0.49 Raises Full-Year Fiscal 2027 Guidance Levels: Total Revenue Range to $368M to $373M and Subsc

SEC EDGAR 8-K6 min
JUN 4
$AGYSMedAI 8/10

Agilysys (AGYS) is Amongst the Most Promising Technology Stocks, Here is Why

Agilysys (NASDAQ:AGYS) reported fiscal 2026 results on May 18. Net sales rose nearly 16% to over $319 million, helped by record recurring revenue of about $206 million and more than 30% subscription revenue growth. Adjusted EBITDA reached nearly $68 million; net income increased to about $39 million ($1.37/share) and free cash flow exceeded $68 million. For fiscal 2027, revenue is forecast at $365–$370 million, with at least 30% subscription growth and ~24% adjusted EBITDA margins.

finance.yahoo.com4 min